A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: This randomised, double-blind, fixed-dose study evaluated the efficacy of escitalopram and paroxetine in the long-term treatment of severely depressed patients with major depressive disorder (MDD).Research design and methods: Patients with a primary diagnosis of MDD and baseline Montgomery-Åsberg Depression Rating Scale (MADRS) ≥ 30 were randomised to 24 weeks of double-blind treatment with fixed doses of either escitalopram (20 mg) (n = 232) or paroxetine (40 mg) (n = 227). The primary analysis of efficacy was an analysis of covariance (ANCOVA) of change from baseline to endpoint (Week 24) in MADRS total score (last observation carried forward, LOCF).Main outcome measures; results: At endpoint (24 weeks), the mean change from baseline in MADRS total score was –25.2 for patients treated with escitalopram (n = 228) and –23.1 for patients with paroxetine (n = 223), resulting in a difference of 2.1 points ( p < 0.05). The difference in the change in the MADRS total score (LOCF) was significantly in favour of escitalopram from Week 8 onwards. The proportion of remitters (MADRS ≤ 12) after 24 weeks was 75% for escitalopram and 67% for paroxetine ( p < 0.05). The results on the primary efficacy scale were supported by significantly greater differences in favour of escitalopram on the Hamilton Anxiety, Hamilton Depression and Clinical Global Impression-Improvement and -Severity scales. For very severely depressed patients (baseline MADRS ≥ 35), there was a difference of 3.4 points at endpoint in the MADRS total score in favour of escitalopram ( p < 0.05). The overall withdrawal rate for patients treated with escitalopram (19%) was significantly lower than with paroxetine (32%) ( p < 0.01). The withdrawal rate due to adverse events was significantly lower for escitalopram (8%) compared to paroxetine (16%) ( p < 0.05). There were no significant differences in the incidence of individual adverse events during treatment.Conclusion: Escitalopram is significantly more effective than paroxetine in the long-term treatment of severely depressed patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Recent developments and current controversies in depression
Ebmeier, K. P., Donaghey, C., & Steele, J. D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67964-6 · Cited by 434
Müller, M. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00120-9 · Cited by 282
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
BELZER, K., & SCHNEIER, F. R. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200409000-00003 · Cited by 235
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“In a 24-week study with severely depressed patients, escitalopram was more effective than paroxetine at 24 weeks and at 8 weeks at a clinically relevant level as judged by the Montgomery–Åsberg Depression Rating Scale (MADRS) difference of two points as well as by the remitter analysis (Boulenger et al., 2006).”
Background(2005) · PubMed · Cited by 221
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Metadata
- Authors
- Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T., & Sarchiapone, M.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2006-06-07
- Volume
- 22
- Issue
- 7
- Pages
- 1331-1341
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2055897579
- Cited by
- 110
- References
- 6
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. https://app.cochat.ai/papers/10.1185/030079906x115513
- The paper
- Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T., & Sarchiapone, M. (2006). A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Current Medical Research and Opinion. https://doi.org/10.1185/030079906x115513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.